Who
Corey S. Goodman
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, ALX Oncology Holdings; 10% owner, Checkmate Pharmaceuticals; 10% owner, Akero Therapeutics; Senior Vice President, Pfizer; President and CEO, Renovis.
In numbers
- Trades disclosed
- 274
- Buys
- 2
- Sells
- 29
- Bought
- $26.1M
- Sold
- $17.4M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 3 Jan 2006
- Last trade
- 2 Feb 2026
- Last filed
- 4 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Feb 2026filed 4 Feb 2026 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Bought | $5.0M3,184,713 at $1.57 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Bought | $5.0M3,184,713 at $1.57 | filing |
| 20 Jan 2026filed 21 Jan 2026 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,400 at $0.00 | filing |
| 20 Jan 2026filed 21 Jan 2026 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,400 at $0.00 | filing |
| 21 Jan 2025filed 23 Jan 2025 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,400 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,200 at $0.00 | filing |
| 20 Jun 2023filed 22 Jun 2023 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,200 at $0.00 | filing |
| 15 Jun 2022filed 16 Jun 2022 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,004 at $0.00 | filing |
| 16 May 2022filed 17 May 2022 | Checkmate Pharmaceuticals | SEC FORM 4 Sold | $1.0M95,800 at $10.45 | filing |
| 13 May 2022filed 17 May 2022 | Checkmate Pharmaceuticals | SEC FORM 4 Sold | $375K35,850 at $10.45 | filing |
| 11 Jun 2021filed 15 Jun 2021 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,004 at $0.00 | filing |
| 21 Jul 2020filed 21 Jul 2020 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,100,020 | filing |
| 21 Jul 2020filed 21 Jul 2020 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —2,398,588 | filing |
| 21 Jul 2020filed 21 Jul 2020 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —490,411 | filing |
| 21 Jul 2020filed 21 Jul 2020 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,052,950 | filing |
| 21 Jul 2020filed 21 Jul 2020 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —78,175 | filing |
| 21 Jul 2020filed 21 Jul 2020 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —15,794 | filing |
| 21 Jul 2020filed 21 Jul 2020 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —52,647 | filing |
| 21 Jul 2020filed 21 Jul 2020 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Code C | —3,100,020 | filing |
| 21 Jul 2020filed 21 Jul 2020 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Bought | $16.1M850,000 at $19.00 | filing |
News
No headline names them, or the companies they trade most, lately.